載入中
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
收盤時
US$5.42
−US$0.38 · -6.55%
盤後
US$5.42
US$0.00 · 0.00%
10月12日 下午4:00 ET
盤中時間採用ET。市場資料可能有所延遲。
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
日內區間
目前US$5.42
52週區間
目前US$5.42
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
91
深度低估
情緒
50
多空交錯
風險
75
高風險
動能
24
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
日內區間
目前US$5.42
52週區間
目前US$5.42
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2235.9萬 USD | 2704萬 USD | 2035.2萬 USD | 2765.6萬 USD | 2051.3萬 USD |
| 銷貨成本 | 969.4萬 USD | 1377.3萬 USD | 1436.8萬 USD | 1800.1萬 USD | 1244.4萬 USD |
| 毛利 | 1266.5萬 USD | 1326.7萬 USD | 598.4萬 USD | 965.5萬 USD | 806.9萬 USD |
| 研究與開發 | 1379.1萬 USD | 2417.9萬 USD | 2024.8萬 USD | 1964.9萬 USD | 1721.9萬 USD |
| 銷售、一般及管理費用 | 3552.9萬 USD | 4683.2萬 USD | 4179.7萬 USD | 4681.6萬 USD | 6235.8萬 USD |
| 營業費用 | 4932萬 USD | 7101.1萬 USD | 6217.3萬 USD | 6646.5萬 USD | 8456.3萬 USD |
| 利息收入 | 94.3萬 USD | 111.6萬 USD | 186.8萬 USD | 50.6萬 USD | 4.4萬 USD |
| 利息支出 | 335.9萬 USD | 9.6萬 USD | 64.5萬 USD | 268.3萬 USD | 8.4萬 USD |
| 折舊和攤銷 | 313.8萬 USD | 742.7萬 USD | 498.5萬 USD | 471.7萬 USD | 445.7萬 USD |
| 營業利益 | −3665.5萬 USD | −5774.4萬 USD | −5618.9萬 USD | −5681萬 USD | −7649.4萬 USD |
| 淨利 | −4171.4萬 USD | −4274.7萬 USD | −5942.7萬 USD | −6219.3萬 USD | −7676.1萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Extended Market ETFVXF48.4萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC11.03萬0.01%13.17億 USD0.60%US$181.66-0.73%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR65160.00%455.91億 USD0.17%US$84.43-0.01%
Dimensional - US Sustainability Core 1 ETFDFSU4056.210.00%23.92億 USD0.15%US$48.13+0.04%
U.S. Micro Cap Portfolio ETFDFMC10860.00%75.58億 USD0.43%US$57.70-0.20%Vanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Sustainability Core 1 ETFDFSUU.S. Micro Cap Portfolio ETFDFMCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
